Probing Mutant KRAS, STK11, KEAP1 in NSCLC

被引：0
|
作者：
Poh, Alissa
机构：
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 10期
关键词：
D O I：
10.1158/2159-8290.CD-NB2022-0054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
According to an exploratory analysis of data from the POSEIDON trial, patients with non-small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings. ©2022 American Association for Cancer Research.
引用
收藏
页码：2226 / 2226
页数：1
相关论文
共 50 条
  • [1] Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC
    Ricciuti, Biagio
    Garassino, Marina Chiara
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (06) : 877 - 882
  • [2] Association of KRAS/STK11/ KEAP1 Mutations and Outcome in the POSEIDON Study: Durvalumab +/- Tremelimumab
    Reinmuth, N.
    Peters, S.
    Cho, B.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S.
    Kim, S.
    Ursol, G.
    Hussein, M.
    Lim, F.
    Yang, C.
    Araujo, L.
    Saito, H.
    Stewart, R.
    Lai, Z.
    Doake, R.
    Krug, L.
    Garon, E.
    Mok, T.
    Johnson, M.
    Eberhardt, W.
    [J]. PNEUMOLOGIE, 2023, 77 : S6 - S6
  • [3] XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
    Li, Xuanzong
    Zou, Bing
    Wang, Shijiang
    Wang, Linlin
    Yu, Jinming
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [4] XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
    Xuanzong Li
    Bing Zou
    Shijiang Wang
    Linlin Wang
    Jinming Yu
    [J]. Journal of Translational Medicine, 19
  • [5] Clinical Outcomes for Patients With Stage III NSCLC and STK11 or KEAP1 Genetic Alterations
    Taasan, S.
    Wolf, S.
    Wang, X.
    Antonia, S.
    Crawford, J.
    Ready, N.
    Stinchcombe, T.
    Clarke, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1042 - S1042
  • [6] Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
    Hempel, L. C.
    de Oliveira, J. Veloso
    Robert, S.
    Hempel, D.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [7] In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
    Kus, Tulay
    Aktas, Gokmen
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : E83 - E84
  • [8] Characterizing SMARCA4/STK11/KEAP1 co-mutant lung adenocarcinoma
    Costa, Emily
    Wohlheiter, Corrin
    Tischfield, Samuel
    Funnell, Alister
    Poirier, J. T.
    Villalonga, Alvaro Quintanal
    Sen, Triparna
    Rudin, Charles
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [9] The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray, Francis
    Routy, Bertrand
    Nassabein, Rami Mohamad
    El Ouarzadi, Omar
    Belkaid, Wiam
    Tran-Thanh, Danh
    Florescu, Marie
    Tehfe, Mustapha
    Blais, Normand
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment? Reply
    V. Alessi, Joao
    Awad, Mark M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : E84 - E85
12345